Online inquiry

IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14979MR)

This product GTTS-WQ14979MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Diseases or disorders including airway inflammation research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14979MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ383MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ7844MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ9970MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ721MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ11242MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ1538MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ12849MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ1019MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW